BATEFENTEROL

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C40H42ClN5O7
Molecular Weight	740.244
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=C(CNC[C@H](O)C2=CC=C(O)C3=C2C=CC(=O)N3)C=C(Cl)C(NC(=O)CCN4CCC(CC4)OC(=O)NC5=CC=CC=C5C6=CC=CC=C6)=C1

InChI

InChIKey=URWYQGVSPQJGGB-DHUJRADRSA-N

InChI=1S/C40H42ClN5O7/c1-52-36-22-33(31(41)21-26(36)23-42-24-35(48)29-11-13-34(47)39-30(29)12-14-37(49)45-39)43-38(50)17-20-46-18-15-27(16-19-46)53-40(51)44-32-10-6-5-9-28(32)25-7-3-2-4-8-25/h2-14,21-22,27,35,42,47-48H,15-20,23-24H2,1H3,(H,43,50)(H,44,51)(H,45,49)/t35-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C40H42ClN5O7
Molecular Weight	740.244
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30880951 | https://clinicaltrials.gov/ct2/show/NCT02570165

Batefenterol, previously known as GSK961081, a bifunctional muscarinic (M2 and M3 receptors) antagonist β2-agonist that is developed for chronic obstructive pulmonary disease (COPD). The drug has successfully completed phase II clinical trials with clinically significant improvements in lung function. No new or unexpected safety signals were observed in this COPD population. The conclusion from the trial was following that batefenterol 300 µg might represent the optimal dose for Phase III studies.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Muscarinic acetylcholine receptor M1 168 Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25100753 \| https://adisinsight.springer.com/drugs/800024247	Antagonist 2849	1.4 nM [Ki]
Muscarinic acetylcholine receptor M3 160 Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25100753 \| https://adisinsight.springer.com/drugs/800024247	Antagonist 2849	1.3 nM [Ki]
Beta-2 adrenergic receptor 209 Target ID: P07550\|\|\|Q53GA6\|\|\|Q9UCZ3 Gene ID: 154.0 Gene Symbol: ADRB2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25100753 \| https://adisinsight.springer.com/drugs/800024247	Agonist 2752	3.7 nM [Ki]

PubMed

Title	Date	PubMed
Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD.	2019-03-19	30880951
A new class of bronchodilator improves lung function in COPD: a trial with GSK961081.	2013-10	23429913
Long-acting muscarinic receptor antagonists for the treatment of respiratory disease.	2013-06	23274274

Patents

Sample Use Guides

In Vivo Use Guide

once-daily batefenterol 37.5, 75, 150, 300, or 600 µg for 42 days administered via dry powder inhaler

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:17:27 GMT 2025` Edited by `admin` on `Mon Mar 31 21:17:27 GMT 2025`
Record UNII	1IAT42T80T
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

batefenterol [INN]

Preferred Name

English

BATEFENTEROL

Official Name

English

GSK961081A

Code

English

Batefenterol [WHO-DD]

Common Name

English

GSK961081

Code

English

BATEFENTEROL [USAN]

Common Name

English

1-(3-((2-CHLORO-4-((((2R)-2-HYDROXY-2-(8-HYDROXY-2-OXO-1,2-DIHYDROQUINOLIN-5-YL)ETHYL)AMINO(METHYL)-5-METHOXYPHENYL)AMINO)-3-OXOPROPYL)PIPERIDIN-4-YL (BIPHENYL-2-YL)CARBAMATE

Systematic Name

English

CARBAMIC ACID, N-(1,1'-BIPHENYL)-2-YL-, 1-(3-((2-CHLORO-4-((((2R)-2-(1,2-DIHYDRO-8-HYDROXY-2-OXO-5-QUINOLINYL)-2-HYDROXYETHYL)AMINO)METHYL)-5-METHOXYPHENYL)AMINO)-3-OXOPROPYL)-4-PIPERIDINYL ESTER

Systematic Name

English

GSK-961081

Code

English

GSK-961081A

Code

English

Code System Code Type Description

INN

9804